Lobe‐specific analysis of perioperative chemotherapy for non‐small cell lung cancer patients

Abstract

Abstract Objectives Perioperative cisplatin‐based chemotherapy decreases the risk of death over surgery alone and is a standard of care. Here, we examined perioperative chemotherapy indications for stage IB‐III non‐small cell lung cancer (NSCLC) patients according to lobe‐specific analysis. Methods Resectable NSCLC patients with stage IB–III who received perioperative chemotherapy with and without radiotherapy after lung resection were identified from the SEER database. Propensity score matching (PSM) analysis was performed to reduce the inherent bias of retrospective studies. The Kaplan–Meier method and log‐rank tests were used to assess the differences in overall survival (OS). Results The study enrolled 23,844 patients before PSM. The perioperative chemotherapy group had better OS than the nonperioperative chemotherapy group in stage IB–III NSCLC patients before and after PSM. However, subgroup analysis according to stage demonstrated that perioperative chemotherapy did not markedly benefit patients with stage IB. Furthermore, lobar subgroup analysis did not show survival advantages in primary tumors located in either the right middle lobe in stages II and III NSCLC or the right lower lobe in stage III NSCLC. Conclusions Lobe‐specific perioperative chemotherapy is recommended in NSCLC patients. For stage IB NSCLC, right middle lobe NSCLC from stage IB‐III and right lower lobe NSCLC from stage III, perioperative chemotherapy might not confer survival benefits.

Keywords

• adjuvant chemotherapy
• lobe‐specific
• neoadjuvant chemotherapy
• NSCLC
• SEER database